Question Bank › Cost of hesitation just flipped

Cost of hesitation just flipped

Cost of hesitation just flipped: management describes buyers no longer able to wait out the decision

Calls Tested
500
Answered YES
3
Hit Rate
0.6%
rare by design

Amgen Inc. (AMGN) — this company's answers

NO on the Q3 2018 call 2018-10-30 B+
The model's full reasoning — Q3 2018 call → NOWe need answer YES/NO. Need analyze transcript. Question asks: does management describe that buyers have recently lost ability to postpone decision, cost of delay increased, and real behavior showing decisions landing. Need identify if any product where management conveys this. Let's scan transcript. Products: Prolia, Repatha, Aimovig, biosimilars, etc. Need see if management describes buyers' cost of inaction rising recently, forcing decisions. For Aimovig: pent-up demand, patients waiting for years, now launching. But is that "cost of delay" changed? Patients suffering from migraine, pent-up demand. Management says "People suffering from migraine and their physicians have been waiting for years for an effective new therapy and they've reacted very well." That suggests unmet need, but not necessarily recent change in cost of waiting. It's new product availability, not buyer's cost of inaction rising. For Repatha: they lowered price to reduce out-of-pocket costs, abandonment rate high. That's about affordability, not cost of delay. For Prolia: osteoporosis, repeat injections. No. Biosimilars? No. Maybe "KYPROLIS" etc? No. Question specifically asks "THE PEOPLE WHO BUY FROM THE COMPANY HAVE RECENTLY LOST THE ABILITY TO POSTPONE THE DECISION" - management conveys waiting has become more expensive/risky for counterparties. Need see if any statement like "patients can no longer wait" or "physicians are forced to act now" due to something. The transcript has "pent-up demand" for Aimovig. But is that a recent change? The product launch itself creates urgency? No, it's new option. The cost of delay for migraine patients has always been high, not recently changed. Management says "patients have been waiting for years" - that implies they could wait until product available. Now they are buying because product exists, not because waiting became more costly. So NO. Also "we expect prescription activity to moderate and normalize" - not sustained forced decisions. Any other? "We have several such products and you can see the benefit of this in the third quarter where our new and recently launched products had double-digit unit volume growth." Not about cost of delay. "With price under pressure, having innovative products which can deliver volume growth by meeting needs of large numbers of patients is ever more important." No. "Repatha...

← Back to the full AMGN analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management describe that THE PEOPLE WHO BUY FROM THE COMPANY HAVE RECENTLY LOST THE ABILITY TO POSTPONE THE DECISION — that is, does management convey that waiting, deferring, or sticking with the status quo has become materially more expensive or more risky for its counterparties than it was until recently, so that buying decisions which used to sit unresolved are now being forced to a conclusion — and does management point to real, current behavior showing that this change in the cost of delay is already producing business? Answer YES when management's own words convey, in whatever form fits the business, ONE coherent phenomenon: something has recently changed such that the counterparty's option to do nothing has become costly, and the buying decisions that follow are now landing on this company. Any genuine expression of this counts, and the form varies widely across industries. For example — management describing that deferred purchases, delayed projects, or postponed replacements can no longer be put off, and those decisions are now being made; buyers whose own operations, obligations, commitments, competitive position, or economics are now visibly penalized for each period they go without what the company provides; customers who had been evaluating, stalling, or living with an older arrangement now moving because the cost of not moving has risen; decisions that used to sit at a lower level or in a queue now being escalated, prioritized, or funded because inaction has consequences; buyers accepting the company's terms, timing, lead times, or price because delay costs them more than the concession; or management explaining that its market has crossed from "customers can wait" to "customers cannot wait" and describing what that has done to orders and conversations. Three things should come through in management's own voice. First, THE CHANGE IS ON THE BUYER'S SIDE AND IS RECENT. Management conveys that something has shifted in the counterparties' own situation — their obligations, economics, operations, competitive pressure, aging assets, commitments to others, or circumstances — that makes standing still expensive in a way it recently was not. This is about the price of inaction having risen for them, not simply about the company's offering being attractive, valuable, or a good investment. Second, IT IS ALREADY SHOWING UP IN REAL BEHAVIOR. Management points to concrete current evidence: orders placed, decisions closed, stalled evaluations now converting, deferred work now released, customers committing sooner or on terms they previously resisted, or activity in the recent period that management attributes to buyers no longer being able to wait. Interest, pipeline, market-size claims, or expectations do not satisfy this. Third, MOST OF IT IS STILL AHEAD. Management conveys, directly or plainly in substance, that the population of counterparties facing this pressure is large relative to what has been served so far, so the reported results reflect only the early part of the decisions now being forced. The essence is ONE phenomenon: the option to wait has been repriced on the other side of the table, and the company sits where the resulting decisions land. The industry, the reason waiting became costly, and the form of the resulting business may vary widely. Answer NO if the offering is described mainly in terms of value, savings, returns, performance, or benefits for the customer, however compelling — attractive economics are not the same as a rising cost of delay. NO if the urgency is only anticipated, or rests on a change management expects rather than one already in force. NO if management merely asserts that its product is essential, mission-critical, or non-discretionary without describing what has changed about the cost of waiting. NO if the urgency described belongs to the company itself rather than to its buyers. NO if the pressure is attributed to a brief disruption, shortage, seasonal deadline, or pre-buy that management expects to unwind. NO if the only evidence is one isolated customer anecdote with no sense of a broader pattern. NO if buyers are described as deferring, stalling, tightening, or waiting for better conditions. NO if the idea appears only in an analyst's question or characterization that management does not itself affirm. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
PFIE Profire Energy, Inc. Q1 2023 2023-05-13 B
BFIN BankFinancial Corporation Q1 2022 2022-05-06 A
HNRG Hallador Energy Company Q3 2021 2021-11-09 C+

How the model reasoned

PFIE · Q1 2023 → YESThe question is about whether management describes that buyers have recently lost the ability to postpone decisions, making waiting more expensive or risky, forcing buying decisions now, and showing c...YES Management describes a clear shift where buyers' deferred maintenance and retrofits—previously postponed—have now become urgent due to pent-up demand and catch-up efforts, with recent behavior showing these decisions are being forced now, and the broader market opportunity still largely ahead.
BFIN · Q1 2022 → YESThe question is about whether management describes that buyers have recently lost the ability to postpone decisions, making waiting more expensive or risky, and this is already producing business, wit...
HNRG · Q3 2021 → YESThe question is about whether management describes that buyers have recently lost the ability to postpone decisions, making waiting more expensive or risky, forcing buying decisions, and showing curre...

More from the question bank

Running the company for a size the numbers dCompounding evidenceThe hard part is already doneRationing itself to growWinning is getting easierEverything is being bought forwardAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.